Anixa Biosciences (ANIX) Other Non-Current Liabilities (2013 - 2017)
Anixa Biosciences' (ANIX) quarterly Other Non-Current Liabilities came in at $4.3 million in Q1 2017, up 13.14% YoY from $3.8 million in Q1 2016, and up 3.39% on a QoQ basis from $4.2 million in Q4 2016.
Anixa Biosciences (ANIX) Other Non-Current Liabilities (2013 - 2017) Analysis & Trends
Anixa Biosciences (ANIX) has 5 years of Other Non-Current Liabilities data on file, last reported at $4.3 million in Q1 2017.
- Quarterly Other Non-Current Liabilities rose 13.14% year-over-year to $4.3 million in Q1 2017, while the trailing twelve-month figure through Jan 2017 was $4.3 million (up 13.14% YoY) and the FY2016 annual result came in at $4.2 million, up 13.11% from the prior year.
- Other Non-Current Liabilities improved to $4.3 million in Q1 2017, from $4.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.3 million in Q1 2017 to a low of $45600.0 in Q2 2013.
- A 5-year average of $3.0 million and a median of $3.4 million in 2014 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2014 — Other Non-Current Liabilities surged 6560.09% — and 2015, when it declined 2.46%.
- Tracing ANIX's Other Non-Current Liabilities over 5 years: stood at $540000.0 in 2013, then soared by 499.31% to $3.2 million in 2014, then increased by 13.96% to $3.7 million in 2015, then climbed by 13.11% to $4.2 million in 2016, then grew by 3.39% to $4.3 million in 2017.
- The last three Other Non-Current Liabilities figures came in at $4.3 million (Q1 2017), $4.2 million (Q4 2016), and $4.1 million (Q3 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Anixa Biosciences | 121.44 Mn | 121.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2017 | 4.31 Mn |
| Oct 31, 2016 | 4.17 Mn |
| Jul 31, 2016 | 4.07 Mn |
| Apr 30, 2016 | 3.94 Mn |
| Jan 31, 2016 | 3.81 Mn |
| Oct 31, 2015 | 3.69 Mn |
| Jul 31, 2015 | 3.57 Mn |
| Apr 30, 2015 | 3.45 Mn |
| Jan 31, 2015 | 3.35 Mn |
| Oct 31, 2014 | 3.24 Mn |
| Jul 31, 2014 | 3.24 Mn |
| Apr 30, 2014 | 3.04 Mn |
| Jan 31, 2014 | 3.43 Mn |
| Oct 31, 2013 | 540,000.00 |
| Jul 31, 2013 | 700,000.00 |
| Apr 30, 2013 | 45,600.00 |